Harrow (NASDAQ:HROW) Shares Gap Down - What's Next?

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $51.80, but opened at $41.75. Harrow shares last traded at $42.99, with a volume of 650,606 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HROW shares. Craig Hallum lifted their target price on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a report on Friday, October 4th. Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Finally, B. Riley restated a "buy" rating and set a $50.00 target price on shares of Harrow in a research report on Thursday, August 29th.

Harrow Stock Performance

The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -45.60 and a beta of 0.76. The firm's 50-day moving average is $47.84 and its two-hundred day moving average is $32.00.

Hedge Funds Weigh In On Harrow

Several large investors have recently modified their holdings of HROW. Quest Partners LLC purchased a new stake in Harrow during the third quarter worth about $29,000. nVerses Capital LLC acquired a new stake in Harrow in the second quarter valued at $33,000. Allspring Global Investments Holdings LLC boosted its position in shares of Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock worth $44,000 after acquiring an additional 2,048 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after acquiring an additional 227 shares during the last quarter. Finally, Hills Bank & Trust Co acquired a new stake in Harrow during the third quarter worth approximately $107,000. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.